Rotschafer JC, Shikuma LR. Pseudomonas aeruginosa susceptibility in a university hospital: recognition and treatment. Drug Intell Clin Pharm. 1986;20:575–81.

CAS  PubMed  Google Scholar 

Parkins MD, Somayaji R, Waters VJ. Epidemiology, biology, and impact of clonal pseudomonas aeruginosa infections in cystic fibrosis. Clin Microbiol Rev. 2018;31:e00019–18.

PubMed  PubMed Central  Article  Google Scholar 

World Health Organization. Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis; World Health Organization: Geneva, Switzerland, 2017.

National Nosocomial Infections Surveillance (NNIS). System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85.

PubMed  Article  Google Scholar 

Dou Y, Huan J, Guo F, Zhou Z, Shi Y. Pseudomonas aeruginosa prevalence, antibiotic resistance and antimicrobial use in Chinese burn wards from 2007 to 2014. J Int Med Res. 2017;45:1124–37.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;48:4606–10.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Curcio D. Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge? Curr Clin Pharm. 2014;9:27–38.

CAS  Article  Google Scholar 

Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–41.

CAS  PubMed  Article  Google Scholar 

Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601.

CAS  PubMed  Article  Google Scholar 

Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and laboratory standards institute and european committee on antimicrobial susceptibility testing position statements on polymyxin b and colistin clinical breakpoints. Clin Infect Dis. 2020;71:e523–e529.

CAS  PubMed  Google Scholar 

Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10:917–34.

CAS  PubMed  Article  Google Scholar 

Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30:557–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Doi Y, van Duin D. Polymyxin resistance in klebsiella pneumoniae: complexity at every level. Clin Infect Dis. 2020;70:2092–4.

CAS  PubMed  Article  Google Scholar 

Chen X, Xu J, Zhu Q, Ren Y, Zhao L. Polymyxin B resistance rates in carbapenem-resistant Pseudomonas aeruginosa isolates and a comparison between Etest® and broth microdilution methods of antimicrobial susceptibility testing. Exp Ther Med. 2020;20:762–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39.

PubMed  PubMed Central  Article  Google Scholar 

Ribera A, Benavent E, Lora-Tamayo J, Tubau F, Pedrero S, Cabo X, et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams. J Antimicrob Chemother. 2015;70:3357–65.

CAS  PubMed  Google Scholar 

Carlson A, Alderete KS, Grant MKO, Seelig DM, Sharkey LC, Zordoky BNM. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. Vet Comp Oncol. 2018;16:253–61.

CAS  PubMed  Article  Google Scholar 

Kuršvietienė L, Stanevičienė I, Mongirdienė A, Bernatonienė J. Multiplicity of effects and health benefits of resveratrol. Med (Kaunas). 2016;52:148–55.

Google Scholar 

Nøhr-Meldgaard K, Ovsepian A, Ingmer H, Vestergaard M. Resveratrol enhances the efficacy of aminoglycosides against Staphylococcus aureus. Int J Antimicrob Agents. 2018;52:390–6.

PubMed  Article  CAS  Google Scholar 

Singkham-In U, Higgins PG, Wannigama DL, Hongsing P, Chatsuwan T. Rescued chlorhexidine activity by resveratrol against carbapenem-resistant Acinetobacter baumannii via down-regulation of AdeB efflux pump. PLoS One. 2020;15:e0243082.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liu L, Yu J, Shen X, Cao X, Zhan Q, Guo Y, et al. Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance. BMC Microbiol. 2020;20:306.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Feng X, Liu S, Wang Y, Zhang Y, Sun L, Li H, et al. Synergistic activity of colistin combined with auranofin against colistin-resistant gram-negative bacteria. Front Microbiol. 2021;12:676414.

PubMed  PubMed Central  Article  Google Scholar 

Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52:4124–8.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Lewis K. Riddle of biofilm resistance. Antimicrobial Agents Chemother. 2001;45:999–1007.

CAS  Article  Google Scholar 

Gupta P, Mankere B, Chekkoora Keloth S, Tuteja U, Pandey P, Chelvam KT. Increased antibiotic resistance exhibited by the biofilm of Vibrio cholerae O139. J Antimicrob Chemother. 2018;73:1841–7.

CAS  PubMed  Article  Google Scholar 

Al-Orphaly M, Hadi HA, Eltayeb FK, Al-Hail H, Samuel BG, Sultan AA, et al. Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region. mSphere. 2021;6:e00202–21.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fernández L, Alvarez-Ortega C, Wiegand I, Olivares J, Kocíncová D, Lam JS, et al. Characterization of the polymyxin B resistome of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57:110–9.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat. 2010;13:132–8.

CAS  PubMed  Article  Google Scholar 

McPhee JB, Bains M, Winsor G, Lewenza S, Kwasnicka A, Brazas MD, et al. Contribution of the PhoP-PhoQ and PmrA-PmrB two-component regulatory systems to Mg2+-induced gene regulation in Pseudomonas aeruginosa. J Bacteriol. 2006;188:3995–4006.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.

PubMed  Article  CAS  Google Scholar 

Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017;61:e02319–16.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang P, Sang S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. Biofactors. 2018;44:16–25.

CAS  PubMed  Article  Google Scholar 

Cannatelli A, Principato S, Colavecchio OL, Pallecchi L, Rossolini GM. Synergistic activity of colistin in combination with resveratrol against colistin-resistant gram-negative pathogens. Front Microbiol. 2018;9:1808.

PubMed  PubMed Central  Article  Google Scholar 

Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomark Prev. 2007;16:1246–52.

CAS  Article  Google Scholar 

Duan J, Li M, Hao Z, Shen X, Liu L, Jin Y, et al. Subinhibitory concentrations of resveratrol reduce alpha-hemolysin production in Staphylococcus aureus isolates by downregulating saeRS. Emerg Microbes Infect. 2018;7:136.

PubMed  PubMed Central  Google Scholar 

Zhou X, Ruan Q, Ye Z, Chu Z, Xi M, Li M, et al. Resveratrol accelerates wound healing by attenuating oxidative stress-induced impairment of cell proliferation and migration. Burns 2021;47:133–9.

PubMed  Article  Google Scholar 

Varricchio AM, Capasso M, Della Volpe A, Malafronte L, Mansi N, Varricchio A, et al. Resveratrol plus carboxymethyl-β-glucan in children with recurrent respiratory infections: a preliminary and real-life experience. Ital J Pediatr. 2014;40:93.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Bonomo RA, Van Zile PS, Li Q, Shermock KM, McCormick WG, Kohut B. Topical triple-antibiotic ointment as a novel therapeutic choice in wound management and infection prevention: a practical perspective. Expert Rev Anti Infect Ther. 2007;5:773–82.

CAS  PubMed  Article